The genetics of pulmonary arterial hypertension.

The Genetics of Pulmonary Arterial Hypertension Eric D. Austin and James E. Loyd Circ Res. 2014;115:189-202 doi: 10.1161/CIRCRESAHA.115.303404 Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2014 American Heart Association, Inc. All rights reserved. Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at: http://circres.ahajournals.org/content/115/1/189

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: http://www.lww.com/reprints Subscriptions: Information about subscribing to Circulation Research is online at: http://circres.ahajournals.org//subscriptions/

Downloaded from http://circres.ahajournals.org/ at BIBLIOTHEQUE DE L'UNIV LAVAL on June 26, 2014

Compendium Circulation Research Compendium on Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension: Yesterday, Today, Tomorrow Pulmonary Arterial Hypertension: The Clinical Syndrome Current Clinical Management of Pulmonary Arterial Hypertension The Metabolic Theory of Pulmonary Arterial Hypertension Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension The Right Ventricle in Pulmonary Arterial Hypertension: Disorders of Metabolism, Angiogenesis and Adrenergic Signaling in Right Ventricular Failure The Genetics of Pulmonary Arterial Hypertension Guest Editor: Evangelos Michelakis

The Genetics of Pulmonary Arterial Hypertension Eric D. Austin, James E. Loyd

Abstract: Pulmonary arterial hypertension (PAH) is a progressive and fatal disease for which there is an everexpanding body of genetic and related pathophysiological information on disease pathogenesis. Many germline gene mutations have now been described, including mutations in the gene coding bone morphogenic protein receptor type 2 (BMPR2) and related genes. Recent advanced gene-sequencing methods have facilitated the discovery of additional genes with mutations among those with and those without familial forms of PAH (CAV1, KCNK3, EIF2AK4). The reduced penetrance, variable expressivity, and female predominance of PAH suggest that genetic, genomic, and other factors modify disease expression. These multi-faceted variations are an active area of investigation in the field, including but not limited to common genetic variants and epigenetic processes, and may provide novel opportunities for pharmacological intervention in the near future. They also highlight the need for a systems-oriented multi-level approach to incorporate the multitude of biological variations now associated with PAH. Ultimately, an in-depth understanding of the genetic factors relevant to PAH provides the opportunity for improved patient and family counseling about this devastating disease. (Circ Res. 2014;115:189-200.) Key Words: bone morphogenetic protein receptor, type II

P

ulmonary hypertension (PH) is an inappropriate elevation of pressure in the pulmonary vascular system attributable to a variety of causes. One subtype of PH is pulmonary arterial hypertension (PAH). PAH is a devastating disease of the pulmonary vasculature that is pathologically characterized by progressive neointimal proliferation, smooth muscle cell hypertrophy, and surrounding adventitial expansion leading to occlusive vascular lesions of the smallest pulmonary arteries.1 Although there are a variety of methods to classify PAH, the most widely applied is the clinical classification system adopted worldwide and recently updated.2 In that

■

genetics

■

hypertension

■

pulmonary

scheme, Group 1 PAH is divided into disease subgroups that include heritable (HPAH, formerly familial PAH), idiopathic (IPAH), and PAH associated with a variety of other systemic diseases or drug/toxin exposures. Despite advancements in therapy during the past 25 years, PAH remains a devastating disease for incident cases with significantly reduced survival.3 Unfortunately, no therapies tested to date have demonstrated ability to reverse or cure PAH. There is a profound need to further our pathophysiologic knowledge to promote novel therapeutic development.3–8

Original received January 7, 2014; revision received April 15, 2014; accepted May 13, 2014. In April 2014, the average time from submission to first decision for all original research papers submitted to Circulation Research was 14.38 days. From the Division of Allergy, Pulmonary, and Immunology Medicine, Department of Pediatrics (E.D.A.) and Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine (J.E.L.), Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN. Correspondence to Eric D. Austin, MD, MSCI, Division of Allergy, Pulmonary, and Immunology Medicine, Department of Pediatric, Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Vanderbilt University, Suite DD-2205, Nashville, TN 37232-2578. E-mail eric. [email protected] © 2014 American Heart Association, Inc. Circulation Research is available at http://circres.ahajournals.org

DOI: 10.1161/CIRCRESAHA.115.303404

Downloaded from http://circres.ahajournals.org/ at BIBLIOTHEQUE DE L'UNIV LAVAL on June 26, 2014 189

190 Circulation Research June 20, 2014

Nonstandard Abbreviations and Acronyms BMPR2 HHT HPAH IPAH miR PAH PCH PH PVOD TGF-β WES

bone morphogenic protein receptor type 2 hereditary hemorrhagic telangiectasia heritable pulmonary arterial hypertension idiopathic pulmonary arterial hypertension microRNA pulmonary arterial hypertension pulmonary capillary hemangiomatosis pulmonary hypertension pulmonary veno-occlusive disease transforming growth factor-β whole-exome sequencing

Table 1. Rare Variants (Mutations) Reported to Associate With PAH Gene Name BMPR2

Epidemiological Factors Relevant to the Genetics of PAH PH is the elevation of pulmonary vascular pressure as determined by invasive hemodynamic assessment by right heart catheterization. A subgroup of PH (Group 1), PAH is defined as a mean pulmonary artery pressure of >25 mm Hg at rest, in the absence of other conditions known to elevate pulmonary vascular pressures, such as left-sided heart disease, hypoxic lung diseases, pulmonary embolism, and various other conditions associated with PH.13,14 Individuals with PAH meet classification for HPAH if they meet any of the following criteria: (1) belong to a family known to have documented PAH in 2 or more individuals (2) possess a rare variant (also known as a mutation) in a gene known to strongly associate with PAH (eg, BMPR2).15 These criteria recognize that many subjects with HPAH do not have a known family history. Important advances in the genetics of PAH during the past 15 years have driven this recognition, as we now know that subjects without a known family history of PAH can have a heritable disease which can be transmitted to their progeny. These subjects would otherwise be considered to have IPAH, but because of reduced penetrance of the known PAH-associated genes, as well as de novo gene changes at conception, these subjects

TGF-β receptor superfamily member ≥80% of familial cases 15% to 25% of IPAH cases

ALK1

TGF-β receptor superfamily member PAH associated with familial HHT Not known to occur distinct from HHT

Endoglin

TGF-β receptor superfamily member PAH associated with familial HHT Not known to occur distinct from HHT

SMAD9

Since its initial descriptions (as primary PH) by Dresdale et al9,10 as a disease that could occur either in isolation or in families in the early 1950s, much has been learned about the molecular and genetic factors that promote PAH. Work in the 1990s and early 2000s led to the discovery that altered bone morphogenic protein receptor type 2 (BMPR2) signaling is the major heritable risk factor for development of PAH, via rare variants (mutations) in the BMPR2 gene.11,12 Since 2000, mutations in other genes related to BMPR2 signaling have been discovered (eg, mutations in ALK1, ENG and SMAD9), and progress has been made in the identification of genetic and epigenetic modifiers of disease expression (Table 1). There has also been a recent explosion in the application of advanced genetic and genomic techniques to uncover novel genomic mechanisms relevant to PAH pathogenesis, making this an exciting time to study the genetic and molecular underpinnings of this devastating disease. The current concepts specific to the genetics of PAH, as well as the ongoing areas of exploration, will be the topic of this review.

Specialized Information

TGF-β superfamily downstream signaling molecule (canonical signaling pathway) Encodes SMAD8

CAV1

Encodes caveolin-1, relevant to caveolar structure as well as nitric oxide signaling Exact estimate of frequency among PAH patients yet to be determined

KCNK3

Encodes TASK-1, a pH sensitive potassium channel Exact estimate of frequency among PAH patients yet to be determined

EIF2AK4 (GCN2)

Association with recessive and sporadic forms of PVOD and PCH Encodes a eukaryotic translation initiation factor superfamily member Exact estimate of frequency among PVOD and PCH patients yet to be determined

All genes associated with autosomal dominant familial disease except for EIF2AK4, which is associated with autosomal recessive PVOD and PCH. HHT indicates hereditary hemorrhagic telangiectasia; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PCH, pulmonary capillary hemangiomatosis; PVOD, pulmonary veno-occlusive disease; and TGFβ, transforming growth factor-β.

actually have previously unrecognized heritable disease.16 Because IPAH is far more prevalent than familial PAH, the largest number of subjects with PAH that is heritable (HPAH) are actually misclassified IPAH who actually have heritable disease.17 While familial PAH and IPAH are histopathologically identical, there are differences among subtypes that influence the clinical presentation and progression of disease.18 Independent of mutation status, historical and more recent data support the notion that incident cases of IPAH are ≈15 times more frequent than familial PAH.17,19 Although hemodynamics tend to be similar between familial PAH and IPAH cases, BMPR2 mutation PAH patients are diagnosed and die ≈10 years earlier than PAH patients without mutation; both IPAH patients and BMPR2 mutation carriers with PAH are exceedingly unlikely to respond to acute vasodilator testing.20–22 However, HPAH associated with mutations in the activin A receptor type IIlike kinase-1 (ACVRL1 or ALK1), a receptor in the transforming growth factor-β (TGF-β) receptor family, have even more severe disease, as suggested by a recent French study. Specifically, they found that ALK1 mutation PAH patients had


Austin and Loyd The Genetics of Pulmonary Arterial Hypertension 191 worse survival compared with BMPR2 carriers and with noncarriers with PAH.23

PAH in Families Well before the discovery of genetic mutations associated with HPAH, it was observed that HPAH is a familial disease transmitted in an autosomal dominant manner. This suggests that heterozygosity for a gene mutation of a major impact is the basis in affected families. But, although an autosomal dominant disease, it does not affect all subjects at risk because of reduced penetrance.24,25 In addition, there is variation in penetrance both within and between families at risk. This reduced penetrance suggests that the presence of a PAHspecific gene mutation is necessary, but insufficient in itself, to cause HPAH.26 While the mechanisms that reduce penetrance are unknown, most investigators agree that it suggests that additional genetic or environmental or both factors modify expression of the disease and may provide clues not only to pathogenesis, but also to potential therapeutic targets.27 Larkin et al28 recently analyzed our HPAH research cohort at Vanderbilt University and calculated the overall penetrance of familial PAH to be 27%. However, consistent with the hypothesis that additional factors modify disease penetrance (such as sex), female penetrance was 42%, while the male penetrance was only 14%. Several additional interesting features of HPAH highlight the variable expressivity of this disease. While the mean age of diagnosis is the mid-30s, it is highly variable.21 Subjects have been diagnosed at virtually any age in the life course, from early childhood to more than 70 years of age. In addition, while not a feature specific to the heritable form of PAH, HPAH does not attack males and females equally (≈2:1 female: male ratio).15,28 However, it is worth noting that one feature traditionally ascribed to HPAH has recently been refuted. Genetic anticipation, characterized by progressively earlier age of onset of a disease in subsequent generations, was suspected to occur among PAH families despite a lack of biological explanation.29–32 However, because of ascertainment bias, proof of genetic anticipation is difficult to achieve without the benefit of several decades of observation. Thus, in an effort to carefully demonstrate the phenomenon in our research cohort, Larkin et al33 recently performed linear mixed effects models and limited time-truncation bias by restricting the date of birth to analyze HPAH families for genetic anticipation. This more rigorous analytic approach demonstrated no evidence to support genetic anticipation. Many clinicians who have treated PAH at the same time in a mother and daughter are impressed by that occurrence, but observing late PAH onset in the daughter’s generation would require many decades of observation. Thus, current evidence does not support genetic anticipation in HPAH.

The Discovery of BMPR2 Gene Mutations in Familial PAH Given the rarity of familial PAH, genetics research benefits immensely from collaborative research efforts and centralized centers for the maintenance of phenotypic and biospecimen

data. In the 1990s, prior to the advent of next-generation sequencing, 2 teams working independently undertook hunts to test the hypothesis that a single gene was responsible for the majority of HPAH cases. They were successful in part because of the collaborative arrangements and large biorepositories at their disposal, which still exist today. Dr Jane Morse led an effort by Columbia University investigators, while an International PH Consortium (a collaborative composed of investigators from Vanderbilt University, University of Leicester, Cincinnati Children’s Hospital Medical Center, and Indiana University) was led by Drs Richard C. Trembath, Rajiv D. Machado, William C. Nichols, and James E. Loyd. Both groups initially used linkage analysis referenced to short tandem repeats and to other microsatellite markers to identify chromosome 2q31-33 as the region associated with PAH in the families studied.34,35 Within a few years, both groups identified BMPR2 as the gene of interest using different approaches. Unknown to the investigators at the time, one heavily affected PAH family was highly genetically informative, and that individual family provided the original evidence suggesting linkage to 2q32 in both groups.36,37 Since these initial reports, BMPR2 gene mutations have been definitively associated with familial PAH, with now more than 400 different mutations in BMPR2 using methods as diverse as direct sequencing, melting curve analysis, DHPLC (denaturing high pressure liquid chromatography), Southern blotting, and multiplex ligation-dependent probe amplification.16 The precise BMPR2 mutation rate in the general population is unknown but thought to be exceedingly low.38 It is now known that mutations in BMPR2 are responsible for ≈75% of the cases of HPAH. Not surprisingly, the discovery of BMPR2 highlighted the relevance of the TGF-β superfamily of receptors and signaling to PAH. And a small percentage of familial PAH cases are also attributed to mutations in other TGF-β family receptor members or related downstream signaling proteins (eg, ACVRL1/ALK1, endoglin/ENG, and SMAD9). While the remaining cases of HPAH that are negative for known mutations may well have as-yet unidentified alterations in genes in the TGF-β pathway such as SMAD9, attention has recently been directed to alternative novel gene mutations.39 As mentioned, mutations at 2 additional loci directly related to the TGF-β superfamily can cause the PAH phenotype in families, although this form of PAH results in conjunction with a broader heritable disease known as hereditary hemorrhagic telangiectasia (HHT). A vascular dysplasia characterized by mucocutaneous telangiectasias, recurrent epistaxis, and gastrointestinal bleeding, HHT is also associated with Group 1 PAH. HHT patients have other vascular abnormalities, however, including arteriovenous malformations of the pulmonary, hepatic, and cerebral circulations, but these findings may be cryptic or develop later in the course. The genes for additional members of the TGF-β signaling superfamily receptor complex, activin receptor-like kinase 1 (ALK1) located on Chromosome 12 and endoglin (ENG) on Chromosome 9, are known to associate strongly with HHT and HHT-associated PAH.40–43 The heterogeneity of loci for mutations in the TGF-β signaling pathway in patients with HPAH suggests that defects in this pathway promote pulmonary vascular disease leading to PAH.


192 Circulation Research June 20, 2014 This is not surprising, as the proteins receptors produced signal intracellularly via the Smad family of coactivators, as well as via some noncanonical pathways of signaling.44,45 Although the precise mechanisms have yet to be elucidated, it is evident that variations at different steps of signal transduction for the TGFβ superfamily of receptors can result in a similar phenotypic expression and that a better understanding of this signaling will improve understanding of HPAH.

BMPR2 in Other Forms of PH The discovery of BMPR2 gene mutations in association with PAH in families highlighted the potential importance of the bone morphogenetic protein (BMP)/TGFβ signaling axis in PAH. Given the similarities between PAH in families and IPAH, naturally, investigators immediately evaluated IPAH cases for an association with the BMPR2 gene despite the absence of familial association. This absence could be explained in many ways, including de novo germline mutations not present in other family members, reduced penetrance, insufficient data for family history, and misdiagnosis.46 As expected, a proportion of IPAH cases do have detectable BMPR2 gene mutations; while the reported proportions are variable, in general ≈15% of IPAH patients (6–40%) actually have HPAH because of a BMPR2 gene mutation.46–49 It is important to note that given that truly idiopathic PAH is 10 to 15 times more common than familial PAH, the vast majority of patients with BMPR2-associated PAH actually have what would otherwise be classified as IPAH. This point highlights the notion that a significant percentage of IPAH cases actually have a heritable disease for which genetic counseling and family screening should be of consideration. In PAH families, the risk is usually obvious and other members are aware, but PAH patients with a negative family history have no clinical basis to suspect risk to their family members. Mutations in BMPR2 and other TGFβ-related genes have not been consistently found in other causes of PH, with some exceptions. For example, some but not all patients with pulmonary veno-occlusive disease (PVOD), a rare form of PH in which the vascular changes also affect small pulmonary veins and venules, possess detectable germline mutations in BMPR2.48,50,51 The detection of BMPR2 mutations in PVOD cases may highlight the clinical heterogeneity that may result from a BMPR2 mutation; that is, perhaps different allelic mutations at a single genetic locus may produce different disease phenotypes. Alternatively, it is possible that PAH and PVOD represent different ends of the same spectra of disease, with the pulmonary blood vessel of primary disease (artery versus vein) influenced by additional genetic or environmental or both modifiers.50 BMPR2 gene mutations were also detected among those subjects with stimulant-related PAH, such as those with PAH because of exposure to appetite suppressants including fenfluramine and dexfenfluramine.52,53 While the precise mechanism remains elusive, these drugs may serve as environmental triggers to promote PAH, possibly in genetically susceptible individuals. Individual factors of susceptibility, or protection, are particularly plausible, given that despite a relatively high exposure rate, the rate of PAH development among stimulant

users is quite low (≈1 case per 10 000 people exposed to fenfluramine, for example).18 Investigators in France described nearly 10% of subjects with stimulant-associated PAH positive for a detectable BMPR2 gene mutation; however, because this proportion is similar to that in sporadic IPAH cases, this may suggest that the presence of a gene mutation is unrelated to the drug exposure. But, it is worth noting that compared with other patients with PAH associated with fenfluramine exposure, BMPR2 mutation carriers expressed disease after a significantly shorter interval of exposure to fenfluramine.54 While a global published assessment of additional groups with PH is lacking, BMPR2 has been explored in congenital heart disease-associated PAH to some extent. While mutations are present at proportions higher than the population at large, the number of subjects with BMPR2 mutations remains small. Specifically, Roberts et al55 detected BMPR2 variations in 6% of 106 children (n=66) and adults (n=40), while in a Thai cohort Limsuwan et al56 found no BMPR2 mutations among 30 children. However, no studies have been published using the expanded genetic analyses currently in use including comprehensive assessment for large gene deletions and duplications, which may uncover additional mutations.57 Given the importance of the BMP pathway to embryological development of the cardiovascular system, additional studies are needed for both the development of CDH and associated PAH. This may be particularly true for atrioventricular canal or septation defects.58 It seems unlikely that mutations will be found in high proportions for other PH groups. For example, BMPR2 mutations were not found in small reports of patients with PAH associated with scleroderma or in HIV-infected patients with PAH.59,60 No BMPR2 mutations were detected in a larger series of 103 patients with chronic thromboembolic PAH.61

Molecular Ramifications of a BMPR2 Gene Mutation While the association of BMPR2 gene mutations with HPAH is no longer of dispute because of the genetic epidemiology available, it is surprising that to date we still do not understand why BMPR2 mutation carriers develop PAH. For example, BMPR2 mutations do not all have the same impact on cell signaling, and there are cell-specific variations even within the pulmonary vasculature. Pulmonary vascular endothelial cells seem dysfunctional and more susceptible to apoptosis in the presence of a BMPR2 mutation.62 However, pulmonary vascular smooth muscle cells with BMPR2 mutations have a failure of growth suppression. It is unclear whether this proproliferative phenotype is attributable to a BMPR2 mutation, or more generically attributable to an increased release of growth factors that promote exuberant smooth muscle cell proliferation by dysfunctional endothelial cells.63 In addition, each mutation type is different and may promote a state of either haploinsufficiency (insufficient protein product and function) or a dominant negative (overtly deleterious protein action) effect. Of note, Bmpr2 knockout rodents do not develop PAH, and dominant negative Bmpr2 mutations knocked in to rodents required an additional insult to improve disease penetrance.64 While some data suggest that


Austin and Loyd The Genetics of Pulmonary Arterial Hypertension 193 dominant negative mutations cause a more severe phenotype, whether reproducible phenotypic differences will emerge is unknown.21,65 A true and comprehensive understanding of the functional impact of BMPR2 (and other gene) mutations on the pulmonary vasculature remains a work in progress. While BMPR2 mutations associated with HPAH are germline and thus presumably present in every cell in the body, the pulmonary vasculature is the site of clinically manifest pathology—this has prompted a long-standing question of why is only the pulmonary vasculature abnormal? This question remains unclear, as there are no consistently reported obviously vascular or other anatomic abnormalities associated with a BMPR2 gene mutation. This is particularly striking, given the known systemic vascular lesions associated with mutations in other TGFβ superfamily genes, such as SMAD3 mutations with aortic aneurysms, as well as fibrillin 1 and other mutations that cause excessive signaling by the TGFβ family of cytokines associated with marfan syndrome.66,67 One possibility is the existence of a lung-specific susceptibility to a disturbance of the presumed balance between canonical TGFβ signaling and BMP signaling—reduced BMP signaling in the setting of normal or enhanced TGFβ signaling promotes PAH pathogenesis.68,69 However, there is now a growing body of data to suggest that while the pulmonary circulation is the site of primary pathology, BMPR2 mutation carriers do have systemic irregularities that may contribute to PAH pathogenesis or maladaptation to ventricular stress. For example, insulin resistance is present as an early feature of Bmpr2 mutation in a dominant negative murine model of PAH, and impaired right ventricular hypertrophy with abundant triglyceride deposition is present in those same mice.70,71 Consistent with this in human patients, Hemnes et al71 recently demonstrated enhanced right ventricular lipid deposition as well as right ventricular defects in fatty acid oxidation. Intriguingly, this may represent a more generalizable manner in which insulin resistance, BMP insufficiency, and PAH intersect.72,73 Current Food and Drug Administration–approved therapeutics for PH do not intentionally include agents that directly modify genetic variants, or their consequences, such as BMPR2 gene mutations. However, such interactions may exist. Also, there is some evidence to suggest that BMPR2 gene mutations result in disruption of pathways related to currently available therapeutics. For example, patients with BMPR2-PAH may have alterations in the endothelin receptor cascade inherent to the presence of the mutations; this could have ramification not only for disease susceptibility but also for pharmacological susceptibility to endothelin receptor antagonists currently used.74 Conversely, treprostinil, a stable prostacyclin analog, inhibits the TGF-β pathway by reducing SMAD3 phosphorylation; this is relevant because exuberant SMAD3 phosphorylation is thought to enhance PAH susceptibility in those with a BMPR2 gene mutation or those with insufficient BMPR2 activity.69,75 Meanwhile, sildenafil enhances BMP signaling and partly restores deficient BMP signaling in the setting of a BMPR2 gene mutation in vitro.76 These findings demonstrate that deficient BMP signaling may be related to current PH-specific pharmaceuticals and suggest that more

work to target BMP signaling may reveal more beneficial compounds.

HPAH Not Attributable to Mutations in the TGFβ Superfamily Related Genes As stated, ≈20% of families lack detectable mutations but clearly demonstrate familial PAH characterized by autosomal dominant transmission. Recent progress in the development of next-generation sequencing platforms has facilitated the opportunity to perform broad, unbiased, evaluations of the exome (and genome) to search for additional mutations which strongly associate with human disease.77 The application of this approach to detect rare variants (mutations) of large impact has prompted the recent discovery of several novel, but biologically plausible, loci which associate with HPAH and may contribute to disease pathogenesis more broadly. In both cases, whole-exome sequencing (WES) was used successfully, with the identification of 2 new PAH-associated genes: KCNK3 and CAV1. Mutations in the gene KCNK3 (Potassium Channel, Subfamily K, Member 3), which encodes the human TASK-1 protein, seem to be the more frequent of the 2 new genetic associations. KCNK3 was reported recently by Ma et al78 based on a collaborative WES study of unrelated PAH families without known PAH gene mutations. Ultimately, 3 PAH families possessed a deleterious missense mutation in KCNK3. After screening a large number of IPAH cases, 3 unrelated IPAH patients were found to possess different missense mutations predicted to have damaging consequences. Each mutation discovered occurred in a highly conserved region of the gene and resulted in loss of function according to electrophysiological studies. Intriguingly, function was partially restored by pharmacological manipulation in vitro. The discovery of KCNK3 was buoyed by strong biological plausibility because it encodes TASK-1, which is a pH-sensitive potassium channel in the 2 pore domain superfamily.79 Ion channels have long been of interest in the pulmonary vascular field, given their potential role not only in vasoconstriction but also in vascular remodeling. While work continues in this area to clarify the biology, there is likely a complicated interplay among ion channels to regulate membrane depolarization via calcium. For example, it seems that reduced potassium channel activity may facilitate calcium-mediated vasoconstriction, which may provide one explanation for the association between KCNK3 mutations and PAH.80 Not surprisingly, for a variety of reasons including the potential channelopathy, most KCNK3 mutants described to date lack response to vasodilator testing. While an independent replication has yet to be published, the KCNK3 discovery, in concert with considerable prior background ion channel research, may propel novel therapeutics because pharmacological manipulation of currents through TASK-1 channels is possible.81 A virtually identical approach was taken by the same collaborative team to study 4 PAH patients from another large family without detectable genetic mutations in the TGF-β pathway, again using WES. In this family the mutation of relevance was ultimately determined to be a rare variant in the caveolin-1 (CAV1) gene, at a highly conserved region


194 Circulation Research June 20, 2014 with a high likelihood of detrimental functional consequences. Subsequent evaluation of an additional 62 unrelated PAH families and 198 IPAH patients (all without detectable BMPR2 mutations) uncovered the independent finding of a de novo CAV1 mutation in an unrelated child with IPAH (both mutations described were frameshift mutations in exon 3: c.474delA [P158P fsX22] and c.473delC [P158H fxX22]). As with the KCNK3 discovery, the variants were genotyped in more than 1000 ethnically matched white, European controls and were not identified in any healthy individuals, supporting the association with PAH.82 While the number of known CAV1 mutants with PAH is low, as with families with TGF-β receptor mutations and KCNK3 mutations, CAV1 mutations seem to associate with PAH with reduced penetrance and variable expressivity. As with TGFβ and KCNK3, biological plausibility for CAV1 is high. Its protein product, caveolin-1, is a membrane protein required to form flask-shaped invaginations of the plasma membrane known as caveolae that function in membrane trafficking, cell signaling, cholesterol homeostasis, and other crucial cellular processes.83–89 Caveolae are abundant in endothelial, adipocyte, mesenchymal, and other cell types.90,91 As with KCNK3, prior research had implicated CAV1, as haploinsufficient mice have airway and pulmonary vascular abnormalities, and expression of caveolin-1 in endothelial cells of the mice rescues many of these defects.92–97 In addition, reduced caveolin-1 endothelial cell staining and expression had been previously reported to occur in the lungs of PAH patients.98–101 But while the finding that CAV1 is mutated in human PAH does not come as a surprise, its specific role in PAH pathogenesis remains incompletely understood. Intriguingly, caveolin-1 seems to modify TGF-β signaling including a reduction in BMP signaling, and separately, reduction in caveolin-1 is associated with hyperactivation of STAT3 which can directly dampen BMP signaling—both these findings provide a mechanistic link between CAV1 and BMPR2 mutations in the pathogenesis of PAH.73,94 In addition, caveolin-1 directly reduces endothelial nitric oxide synthase activity, and loss of caveolin-1 prompts pathological exuberant endothelial nitric oxide synthase activity such that mice null for caveolin-1 develop PH.102 Recent human and rodent investigations suggest that activated CD47 suppresses caveolin-1, which allows uncoupled endothelial nitric oxide synthase to produce pathological reactive oxygen species that promote PAH.93,96,100,101,103 As with KCNK3, the distinct but potentially interwoven mechanisms by which caveolin-1 deficiency alters cell function may be a prime target for novel therapeutic development.

Novel Gene Discoveries Related to the PAH Phenotype The clinical presentation of rare subsets may be identical to that of PAH. PVOD and pulmonary capillary hemangiomatosis (PCH) have PH which may be difficult to distinguish from each other and from PAH. As such, the current classification scheme contains these diagnoses together in a single subcategory of Group 1 PAH. This subcategory is labeled as 1′: PVOD or PCH or both.1,2 Recent findings further validate their inclusion together.

Two separate investigative groups recently performed WES to identify novel mutations successfully in the same gene associated with PVOD and PCH. By studying different unrelated families, both groups reported that EIF2AK4 (also known as GCN2) gene mutations associate with familial disease transmitted in an autosomal recessive form. EIF2AK4 encodes Eukaryotic Translation Initiation Factor 2 Alpha Kinase, a serine-threonine kinase. In the recessive form, unlike BMPR2/KCNK3/CAV1 mutations and familial PAH (an autosomal dominant disease), patients possessed deleterious gene mutations for both alleles of the EIF2AK4 gene. In addition, PVOD and PCD patients with negative family history were also associated with mutations in this gene, suggesting previously unrecognized heritable disease. Investigators in France focused their study on recessive PVOD and found biallelic mutations in EIF2AK4 present in all the 13 families studied. In addition, 5/20 (25%) of sporadic PVOD cases had biallelic mutations, similar to the percentage of IPAH cases with a single-allele BMPR2 mutation to explain their PAH. In total, 22 distinct EIF2AK2 mutations were detected, all of which seemed detrimental to gene function, and strong background evidence was provided to support the notion that EIF2AK2 mutations are a common basis for PVOD. While penetrance of the gene mutation was difficult to assess because of low numbers, as with BMPR2 (and ALK1) and autosomal dominant PAH, patients with EIF2AK4 mutations had variable age at diagnosis but were significantly younger than PVOD patients without mutation.104 Not surprisingly, 2 patients were initially diagnosed with PCH, which can be difficult to distinguish clinically and histopathologically from PVOD.105 In fact, the authors further support their contention that PCH and PVOD represent the same disease. Independently, a US collaborative team was focused on autosomal recessive PCH cases and discovered biallelic EIF2AK4 gene mutations, again using a WES approach. In addition to a family with recessive PCH, EIF2AK4 gene mutations were detected in 2/10 (20%) sporadic PCH cases. Not surprisingly, for some of these patients, distinction from PCH and PVOD was challenging at the time of phenotypic determination.106 The discovery of this novel genetic association for PVOD and PCH supports the assertion that these 2 disease entities represent a single disease spectrum. This role for genetic findings to assist with complicated phenotypic classification is relatively new to the field of PH. EIF2AK4 mutations also confirm the heritable nature of these diseases and may provide critical consideration for genetic counseling of these patients in the future. Hopefully, novel molecular and therapeutic advances will rapidly emerge, as well as extension of these studies to additional patients with PVOD and PCH.

Beyond Heritable Gene Mutations: Genetic Modifiers and Novel Associations With Human PAH It is clear that no genetic variation, be it rare mutation or common variation, will occur in isolation in a given person. There is growing information to suggest that additional genetic and nongenetic factors exist and modify the development (or not)


Austin and Loyd The Genetics of Pulmonary Arterial Hypertension 195 of PAH among susceptible individuals (Figure 1). Among those with a BMPR2 gene mutation, the lack of complete penetrance implies that a mutation in the BMPR2 gene is required but insufficient alone for phenotypic expression. Among those without a single PAH gene mutation, alternative genetic risk factors likely exist. During the past 15 years, multiple candidate genes and genetic factors have emerged although all require additional investigation or have not yet been convincingly replicated.68,107–113 Here we briefly present several promising areas of investigation which may ultimately shed light on PAH pathogenesis.

Activity of the Wild-Type BMPR2 Allele There is an accepted reduction in BMPR2 immunostaining from the lungs of patients with familial and idiopathic PAH regardless of BMPR2 mutation status.114 Thus, factors that regulate the production of BMPR2 protein by mutated and wild-type BMPR2 alleles may be relevant. Examining subjects with BMPR2 mutations, Hamid115 recently demonstrated that the level of production of BMPR2 transcript and protein by the wild-type allele was associated with disease penetrance in the setting of a haploinsufficient BMPR2 mutation. In that situation, the wild-type BMPR2 allele was the major determinant transcript and protein production. Mutation carriers with HPAH had lower wild-type BMPR2 transcript levels compared with unaffected mutation carriers with the same mutation PAH. Thus, BMPR2 production by the wild-type allele seems to modify disease penetrance among genetically susceptible individuals and might be a novel therapeutic target for disease prevention. It may also explain the virtual absence of BMPR2 protein detectable by

immunohistochemistry of the lungs from HPAH patients with a BMPR2 mutation.114 Work is currently being done to evaluate this finding more broadly among BMPR2 mutation carriers and other subjects at risk of PAH.

Somatic Lung Mutations While the traditional approach in the PAH field is to assess for inherited germline mutations in BMPR2 and other genes, Aldred et al116 recently studied the lungs from 2 BMPR2 mutation carriers with HPAH in the search for a second hit which may occur de novo in the lungs. They found a somatic mutation within chromosome 13 in a location that includes the SMAD9 gene in 1 subject, suggesting an additional insult to BMP signaling. While this novel finding has yet to be replicated, it supports the concept that somatic mutations in the lungs could promote or modify disease penetrance among susceptible individuals, which is a concept well described in other fields, such as cancer biology.117

Common Genetic Variations: CBLN2 Perhaps the most promising common genetic variation described to date with regard to PAH pathogenesis may be that which emerged from a recent multinational genomewide association study (GWAS) of familial and idiopathic PAH cases without BMPR2 gene mutations. In this search for common genetic variations associated with PAH led by French investigators, 2 independent case–control studies were undertaken including 625 PAH cases and 1525 healthy control subjects. Germain et al118 identified a significant association at the 18q22.3 locus, with an odds ratio for PAH of nearly 2.0. They focused their finding on the CBLN2 gene, which belongs to the cerebellin gene family related to secreted neuronal glycoproteins. While not previously associated with lung disease, they found that mRNA levels of CBLN2 were significantly higher in PAH lungs compared with controls, as well as from cultured PAH-derived endothelial cells. While considerable additional work will be needed to determine the precise role of CBLN2 in PAH, it is believed that it may modify cellular proliferation locally within the lung.

Common Genetic Variations: Sex Hormones

Figure 1. Major factors in the development of pulmonary arterial hypertension (PAH). Heterozygosity for the presence of a rare variant (mutation) in a gene known to associate with PAH is a major risk factor (eg, BMPR2 gene mutation). However, subjects with these mutations do not always develop PAH, suggesting that the mutations are generally not sufficient to cause PAH in isolation. Additional factors are likely to contribute to disease penetrance in the genetically susceptible individual. Some of the potential factors, which may also contribute to other forms of PAH, are noted.

PAH has long been known to preferentially affect females more than males, which suggests that factors associated with sex contribute to pathogenesis.9,17 While chromosomal differences (XX versus XY) or aberrant X-inactivation may contribute, there is a paucity of supportive data.116 However, there is a growing body of literature to implicate sex hormones in PAH pathogenesis epidemiologically as well as based on in vitro, in vivo, and human data. For example, MacLean et al119 and White et al120 used a genetic-based model of rodent PAH, using manipulation of the serotonin transporter (SERT), to develop a model of PAH which demonstrated female excess. They used hypoxia to show that female mice that overexpress the SERT (SERT+ mice) exhibit PAH and exaggerated hypoxia-induced PAH, while male SERT+ mice do not. Furthermore, ovarian removal abolished the PAH in the female mice, while estradiol re-established the PAH phenotype. This model’s link of female sex hormones with enhanced serotonin activity



Figure 2. Simplified schematic of the proteins encoded by the genes with mutations known to associate with pulmonary arterial hypertension (PAH), with a focus on the BMP signaling pathway but addition of recently described mutations. Genes with mutations known to associate with PAH include BMPR2, ALK1, Endoglin, Smad9 (encodes SMAD 8), CAV1, KCNK3, and EIF2AK4. Possible resultant signaling or effects of protein actions are briefly listed. Of note, Smad-independent effects of BMP signaling abnormalities are not shown but may contribute to PAH pathogenesis, such as alterations in cytoskeletal dynamics, cell survival, and mitochondrial metabolism. BMPR2 indicates bone morphogenic protein receptor type 2; and TGF-β, transforming growth factor-β.

presents an intriguing biological and epidemiological connection, in part because common genetic variations in SERT have been investigated previously in PAH with mixed conclusions.109–111,120,121 Aberrant sex hormone metabolism has been recently implicated in the pathogenesis of human PAH. Using expression arrays from BMPR2 mutants, West et al122 found a major difference in the gene CYP1B1. CYP1B1, which encodes an estrogen metabolizing enzyme, had 10-fold lower expression levels in female mutation carriers with PAH compared with those without PAH. CYP1B1 metabolizes parent compound estrogens to 2-hydroxy and 4-hydroxy metabolites.123 These metabolites are less estrogenic than the 16-α-hydroxy metabolites, which seem to be mitogenic and proproliferative.124,125 We followed up this work to investigate common genetic polymorphisms in CYP1B1 linked to estrogen metabolite levels. While a larger replication study is underway, the results were consistent with West’s array study. BMPR2 mutation penetrance was 4-fold higher for those homozygous for the less active N/N CYP1B1 allele compared with those who were heterozygous (N/S) or homozygous (S/S) for the Asn453Ser polymorphism. In the nested case–control portion of the study, the 2-OHE/16α-OHE1 ratio was 2.3fold lower among female HPAH patients compared with the healthy mutation carriers.126 Of course, the influence of female and male sex hormones and their metabolites is likely much more complicated than this study could adequately represent. But there are now data to suggest that sex hormones and their metabolites themselves contribute to BMPR2-mediated PAH. Other work by Roberts et al127 simultaneously supported the role of sex hormones in the pathogenesis of portopulmonary hypertension, another form of PAH. They found that common variations in genes related to both estrogen signaling and cell growth regulators associated with portopulmonary hypertension, including the gene coding for estrogen receptor 1. In

addition, for the gene that encodes aromatase (CYP19A1), which is the rate-limiting step in the conversion of androgens to estradiol, common polymorphic variation was associated with increasing levels of estradiol in a dose-dependent fashion, regardless of sex.

Epigenetics in the Pathogenesis of PAH The wide variety of causes of PAH, and the lack of unifying DNA variants across all causes, even among those with familial PAH, suggest that non–DNA based cellular memory contributes to PAH pathogenesis. There is thus growing interest in the contribution of epigenetic mechanisms. These heritable, often self-perpetuating yet reversible variations may be of a variety of types such as CpG island methylation by DNA methyltransferases, noncoding RNAs, and perhaps histone modification. For example, Archer et al128 recently identified CpG island hypermethylation as an epigenetic cause of mitochondrial superoxide dismutase-2 deficiency in experimental PH, consistent with prior human lung data with superoxide dismutase-2 reduction. In addition, there is tremendous current interest in the contribution of microRNAs (miRs) to the pathogenesis of PAH. Many miRs have been implicated in human PAH to date (eg, miR-17/92 cluster, miR-26a, miR27a, miR-124, miR-145, miR-150, miR-204, miR-206) with some but not all related to alterations in BMP signaling or other pathways such as DNA damage and repair, although additional studies are needed.129–131 These and other avenues of progress in understanding the genetic and genomic factors that promote PAH in the susceptible, and theoretically not susceptible, individual provide tremendous opportunities for discovery and progress in the PAH field. The current era of next-generation sequencing provides tremendous opportunity to expand our understanding of PAH pathogenesis and hopefully lead to therapeutic and curative therapies. For example, the evaluation of large numbers of subjects by wholeexome, whole-genome, and RNA sequencing techniques offers the promise that one day very soon comprehensive systems biology approaches will provide new breakthroughs. We should


Austin and Loyd The Genetics of Pulmonary Arterial Hypertension 197 have the capacity to overlay complicated layers of informative data together to provide impactful understanding of all types of PAH, regardless of subtype.

Genetic Testing for PAH Genetic testing for known mutations in PAH-associated autosomal dominant genes is available in North America and Europe for the BMPR2, ALK1, ENG, SMAD9, CAV1, and now KCNK3 genes (Figure 2). There currently is no unified PAH mutation panel incorporating all genes in North America, but one may emerge soon. Unless there is a known family history of HHT or a strong clinical suspicion of HHT, clinical mutation testing specific to PAH should begin with testing for BMPR2 mutations given the higher prevalence. Aside from familial and idiopathic PAH, no other forms of PH justify clinical mutation testing at this time. Incorporation of testing for common genetic variants into the clinical testing approach is also not recommended at present. Provision of genetic counseling by trained professionals is vital before and after undertaking clinical genetic testing.38 Pre-test informed consent and counseling, supported by counseling at the time of result provision, should ensure that all involved understand the possible results of the testing and what these results might imply for both the patient and family members. Reduced penetrance is one of the many reasons why this is crucial.28 Furthermore, current mutation testing does not account for the contribution of alternative genetic and nongenetic modifiers of disease expression. The pediatric PAH patient presents similar challenges with regard to clinical genetic testing, with some additional issues of consideration. In general, the notion of genetic testing is more prevalent within the broader context of complex pediatric disease, and thus testing for PAH-associated genetic variants may actually be more common in pediatric PAH although data in this regard are lacking. Overall, the same principles of genetic testing in pediatrics apply as for adults. However, it is critical to keep in mind that clinical genetic testing should be used for the evaluation of the patient and not strictly for the purposes of familial-based risk assessment. Because, while the detection of a PAH-associated gene mutation can be highly informative to assess familial risk for siblings, parents, etc, given the lack of autonomy of the child, this should not be the primary reason for genetic testing of the pediatric patient without extensive pre- and post-test counseling. More typically, mutation testing may be incorporated as part of a broader evaluation as to the pathogenesis of the PAH, although this is not a mandatory component of PAH evaluation. For the asymptomatic offspring of a BMPR2 mutation carrier, there is a 50% chance of inheriting the BMPR2 gene mutation from the parent. A negative genetic screen is extremely reassuring—the absence of the implicated mutation takes the subject’s PAH risk to near zero. But the presence of a detectable mutation doubles lifetime pretest probability risk. Because the pretest probability of PAH is higher for a female (0.5×0.42=0.21) than a male (0.50×0.14=0.07), disease risk is not equal. For a male the detection of the family BMPR2 mutation changes the risk from ≈7% to 14% in a

lifetime. For a female, the detection of the family BMPR2 mutation changes the risk from ≈21% to 42% in a lifetime. While additional studies are needed, many investigators suspect that the presence of a BMPR2 mutation associates with at least subtle pulmonary vascular developmental and functional abnormalities such as an enhanced pressure response to hypoxia.132 Genetic testing for IPAH cases deserves consideration, although this topic is controversial in the field. For incident IPAH cases, the detection of a BMPR2 mutation could prompt substantial anxiety because of the concern for one’s family. The significant emotional stress both for the patient, who can experience what has been termed the guilt of heritability, and for informed family members can be a significant burden.133 In contrast, the discovery of a heritable disease in theory could provide the opportunity for family screening and closer observation in the hope of earlier disease detection. However, there is no practice guideline for the management of individuals who have tested positive for a mutation but are currently without signs or symptoms of PAH. While needed, there have been no studies to determine the best strategy for screening and early detection of clinically significant disease. At a minimum, such individuals should have clinical noninvasive echocardiographic screening every 3 to 5 years.134 Compliance with this recommendation is unknown and has not been reported. There is a growing list of PH-specific therapies, some of which have been used extensively in subjects without PH (eg, sildenafil and tadalafil for erectile dysfunction), which one day could be used as a means of primary prevention for those at significant risk of developing PAH (eg, healthy BMPR2 mutation carriers in families with known familial PAH). However, there are no current data to support or refute such an approach. Primary prevention trials for PHspecific therapies are needed to determine what drugs to select, if they are helpful, and the optimal time to initiate. This is crucial because PH-specific therapies are expensive, complicated, disruptive to normal routines, and can have significant side effects.

Global Conclusions Tremendous progress has been made to mature our understanding of the genetic basis of PAH since the initial descriptions of BMPR2 gene mutations in familial PAH. In particular, the next-generation sequencing and genomics revolutions currently underway have propelled progress during the past 5 to 10 years. However, fundamental questions remain to be answered. The future of PAH research must blend all data sources to provide a more comprehensive understanding of the complex biological networks and events that promote PAH in the susceptible individual.135 Such a systems-oriented multi-level framework will be critical as we recognize that genetic and other types of variations rarely occur in isolation. The inherent complexity of molecular events over time, in concert with environmental exposures, must be understood to ultimately determine the critical major and minor variations which intersect to promote a PAH phenotype. Only then can we optimally harness the genetic, and growing genomic, progress to modify this devastating human disease.



A Patient Asks Questions… Why me? I am not aware of anybody else in my family ever being diagnosed with this disease, dying prematurely, or having similar symptoms. Our patient is understandably concerned about the implications of her recent diagnosis of idiopathic pulmonary arterial hypertension (PAH). Despite a lack of family history, ≈20% of idiopathic PAH patients have a detectable mutation in a gene known to associate with PAH. This is most commonly a mutation in the gene bone morphogenic protein receptor type 2 (BMPR2). While the therapeutic implications of the detection of a BMPR2 mutation are not currently relevant to a patient with PAH, researchers are actively pursuing this issue for future therapeutic development. I wish to have children. Should I be concerned about passing this disease to my children and are there any tests that I can take to know for sure? Our patient wisely raises the issue of reproduction. There is an option to consider gene mutation testing, including BMPR2. This should be performed in concert with the patient’s PH physician and include informed genetic counseling perhaps with a genetic counselor to facilitate the discussion. If the patient elects to pursue mutation testing, and she does turn out to possess a mutation in BMPR2, this could be of concern for her children. Because BMPR2-associated PAH is an autosomal dominant disease, theoretically the inheritance of 1 BMPR2 mutation dramatically increases PAH susceptibility. However, because of reduced penetrance, possession of a BMPR2 mutation is not a guarantee that a person will ever develop PAH in their lifetime. The risk of developing PAH for those who have a pathogenic BMPR2 gene mutation is ≈20% (this risk is not equal for males and females, but we will use 20% for simplicity). Thus, a rough calculation of the risk of a person’s child to develop PAH because of a parent with BMPR2-associated PAH is as follows: Issue One: 50% chance a parent with a BMPR2 mutation will pass that mutation to her child. Issue Two: 20% chance a person with a BMPR2 mutation will develop PAH in their lifetime Mathematical Estimation: 0.50×0.20=0.10=10% risk that the patient’s child will ever develop PAH. Mutation testing for PAH-related genes should occur in a clinical laboratory experienced in the assays to detect mutations in these genes. Several such laboratories are now available on each continent for clinical genetic testing. Pre-test and postgenetic counseling is an important component of the testing for patients and their families. It is also important to know that pregnancy by itself poses a risk for the mother with PAH, for which there are many reasons, including the fact that the retention of fluids in the body caused by pregnancy poses additional stress on the function of the right heart chambers, which is often already compromised at that point. The worsening in the heart function may put in danger the life of the mother and the fetus. While it is possible that a pregnancy in a patient with PAH can be completed successfully, it is considered a high-risk pregnancy and requires very careful management by many specialists, prolonged monitoring, and hospitalization. For the case description, see introductory article by E.D. Michelakis, page 109.

Acknowledgments We thank the many patients and families from around the world who graciously contributed to the studies reviewed.

Sources of Funding This work was supported in part by National Institutes of Health grants (P01 HL 072058 [prinicpal investigator: J.E. Loyd], R01 HL 111259 [prinicpal investigator: J.E. Loyd], and K23 HL 098743 [prinicpal investigator: E.D. Austin]).

Disclosures None.

References 1. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–D50. 2. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF,

Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–D41. 3. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–163. 4. Blasko E, Haskell CA, Leung S, et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol. 2009;214:67–77. 5. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549–555. 6. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477–1482. 7. Zhang R, Dai LZ, Xie WP, Yu ZX, Wu BX, Pan L, Yuan P, Jiang X, He J, Humbert M, Jing ZC. Survival of Chinese patients with pulmonary arterial hypertension in the modern management era. Chest. 2011;140:301-309. 8. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010;138:1234–1239. 9. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med. 1951;11:686–705.


Austin and Loyd The Genetics of Pulmonary Arterial Hypertension 199 10. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med. 1954;30:195–207. 11. Deng Z, Haghighi F, Helleby L, Vanterpool K, Horn EM, Barst RJ, Hodge SE, Morse JH, Knowles JA. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med. 2000;161:1055–1059. 12. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in bmpr2, encoding a tgf-beta receptor, cause familial primary pulmonary hypertension. The international pph consortium. Nat Genet. 2000;26:81–84. 13. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55–S66. 14. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. Accf/aha 2009 expert consensus document on pulmonary hypertension a report of the American College Of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–1619. 15. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–S54. 16. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA III, Soubrier F, Trembath RC, Chung WK. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S32–S42. 17. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Int Med. 1987;107:216–223. 18. Sztrymf B, Yaïci A, Jaïs X, Sitbon O, Simonneau G, Humbert M. Idiopathic pulmonary hypertension: what did we learn from genes? Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(suppl 1):S91–S100. 19. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–1030. 20. Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S, McGoon MD, Scholand MB, Kim M, Jensen RL, Schmidt JW, Ward K. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation. 2006;113:2509–2515. 21. Austin ED, Phillips JA, Cogan JD, Hamid R, Yu C, Stanton KC, Phillips CA, Wheeler LA, Robbins IM, Newman JH, Loyd JE. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res. 2009;10:87. 22. Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med. 2008;177:1377–1383. 23. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jaïs X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, Sitbon O, O’Callaghan DS, Simonneau G, Soubrier F, Humbert M. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med. 2010;181:851–861. 24. Loyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis. 1984;129:194–197. 25. Loyd JE, Slovis B, Phillips JA III, Butler MG, Foroud TM, Conneally PM, Newman JH. The presence of genetic anticipation suggests that the molecular basis of familial primary pulmonary hypertension may be trinucleotide repeat expansion. Chest. 1997;111:82S–83S. 26. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719–725. 27. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation. 2005;111:607–613. 28. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, West JD, Phillips JA III, Hamid R, Loyd JE. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:892–896. 29. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA III, Newman JH. Genetic anticipation and abnormal gender ratio at birth in

familial primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;152:93–97. 30. Sztrymf B, Yaici A, Jais X, Simonneau G, Sitbon O, Humbert M. [Genetics of pulmonary arterial hypertension: recent data and practical applications]. Rev Mal Respir. 2005;22:796–805. 31. Pearson CE, Nichol Edamura K, Cleary JD. Repeat instability: mechanisms of dynamic mutations. Nat Rev Genet. 2005;6:729–742. 32. Armanios M, Chen JL, Chang YP, Brodsky RA, Hawkins A, Griffin CA, Eshleman JR, Cohen AR, Chakravarti A, Hamosh A, Greider CW. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A. 2005;102:15960–15964. 33. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, West JD, Phillips JA III, Hamid R, Loyd JE. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:892–896. 34. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, Siemieniak DR, Wheeler L, Phillips JA III, Newman JH, Conneally PM, Ginsburg D, Loyd JE. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet. 1997;15:277–280. 35. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC, Nygaard TG. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation. 1997;95:2603–2606. 36. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67:737–744. 37. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in bmpr2, encoding a tgf-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81–84. 38. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004;43:33S–39S. 39. Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet. 2009;46:331–337. 40. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13:189–195. 41. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345–351. 42. Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies alk-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet. 2003;40:865–871. 43. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001;345:325–334. 44. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700. 45. Fernández-L A, Sanz-Rodriguez F, Blanco FJ, Bernabéu C, Botella LM. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. Clin Med Res. 2006;4:66–78. 46. Machado RD, Aldred MA, James V, et al. Mutations of the tgf-beta type ii receptor bmpr2 in pulmonary arterial hypertension. Hum Mutat. 2006;27:121–132. 47. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding bmpr-ii, a receptor member of the tgf-beta family. J Med Genet. 2000;37:741–745. 48. Aldred MA, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez MA, Martensson G, Galie N, Manes A, Corris P, Simonneau G, Humbert M, Morrell NW, Trembath RC. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat. 2006;27:212–213. 49. Fujiwara M, Yagi H, Matsuoka R, Akimoto K, Furutani M, Imamura S, Uehara R, Nakayama T, Takao A, Nakazawa M, Saji T. Implications of mutations of activin receptor-like kinase 1 gene (alk1) in addition to bone morphogenetic protein receptor ii gene (bmpr2) in children with pulmonary arterial hypertension. Circulation. 2008;72:127–133.


200 Circulation Research June 20, 2014 50. Runo JR, Vnencak-Jones CL, Prince M, Loyd JE, Wheeler L, Robbins IM, Lane KB, Newman JH, Johnson J, Nichols WC, Phillips JA III. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med. 2003;167:889–894. 51. Montani D, Achouh L, Dorfmuller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87:220–233. 52. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S–12S. 53. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335:609–616. 54. Humbert M, Deng Z, Simonneau G, Barst RJ, Sitbon O, Wolf M, Cuervo N, Moore KJ, Hodge SE, Knowles JA, Morse JH. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J. 2002;20:518–523. 55. Roberts KE, McElroy JJ, Wong WP, Yen E, Widlitz A, Barst RJ, Knowles JA, Morse JH. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 2004;24:371–374. 56. Limsuwan A, Choubtum L, Wattanasirichaigoon D. 5′UTR repeat polymorphisms of the BMPR2 gene in children with pulmonary hypertension associated with congenital heart disease. Heart Lung Circ. 2013;22:204–210. 57. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA III, Soubrier F, Trembath RC, Chung WK. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S32–S42. 58. Délot EC, Bahamonde ME, Zhao M, Lyons KM. BMP signaling is required for septation of the outflow tract of the mammalian heart. Development. 2003;130:209–220. 59. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol. 2002;29:2379–2381. 60. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Hervé P, Barst RJ, Simonneau G. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;167:1433–1439. 61. Suntharalingam J, Machado RD, Sharples LD, Toshner MR, Sheares KK, Hughes RJ, Jenkins DP, Trembath RC, Morrell NW, Pepke-Zaba J. Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax. 2007;62:617–622. 62. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, Karoubi G, Courtman DW, Zucco L, Granton J, Stewart DJ. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98:209–217. 63. Yang X, Long L, Reynolds PN, Morrell NW. Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells. Pulm Circ. 2011;1:103–110. 64. West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, Albu S, Stewart D, Fagan K. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol. 2008;295:L744–L755. 65. Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med. 2008;177:1377–1383. 66. van de Laar IM, van der Linde D, Oei EH, et al. Phenotypic spectrum of the smad3-related aneurysms-osteoarthritis syndrome. J Med Genet. 2012;49:47–57. 67. Hayward C, Keston M, Brock DJ, Dietz HC. Fibrillin (FBN1) mutations in Marfan syndrome. Hum Mutat. 1992;1:79. 68. Phillips JA III, Poling JS, Phillips CA, Stanton KC, Austin ED, Cogan JD, Wheeler L, Yu C, Newman JH, Dietz HC, Loyd JE. Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension. Genet Med. 2008;10:359–365. 69. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc. 2006;3:680–686.

70. West J, Niswender KD, Johnson JA, Pugh ME, Gleaves L, Fessel JP, Hemnes AR. A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J. 2013;41:861–871. 71. Hemnes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleaves L, Talati M, Absi T, Disalvo T, West J. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med. 2014;189:325–334. 72. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007;115:1275–1284. 73. Meloche J, Courchesne A, Barrier M, et al.. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc. 2013;2:e005157. 74. Talati M, West J, Blackwell TR, Loyd JE, Meyrick B. BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;299:L363–L373. 75. Ogo T, Chowdhury HM, Yang J, Long L, Li X, Torres Cleuren YN, Morrell NW, Schermuly RT, Trembath RC, Nasim MT. Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2013;48:733–741. 76. Yang J, Li X, Al-Lamki RS, Wu C, Weiss A, Berk J, Schermuly RT, Morrell NW. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2013;33:34–42. 77. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, Shendure J. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12:745–755. 78. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med. 2013;369:351–361. 79. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, Wilhelm J, Morty RE, Brau ME, Weir EK, Kwapiszewska G, Klepetko W, Seeger W, Olschewski H. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res. 2006;98:1072–1080. 80. Kuhr FK, Smith KA, Song MY, Levitan I, Yuan JX. New mechanisms of pulmonary arterial hypertension: role of Ca²+ signaling. Am J Physiol Heart Circ Physiol. 2012;302:H1546–H1562. 81. Streit AK, Netter MF, Kempf F, Walecki M, Rinné S, Bollepalli MK, Preisig-Müller R, Renigunta V, Daut J, Baukrowitz T, Sansom MS, Stansfeld PJ, Decher N. A specific two-pore domain potassium channel blocker defines the structure of the TASK-1 open pore. J Biol Chem. 2011;286:13977–13984. 82. Austin ED, Ma L, LeDuc C, Berman Rosenzweig E, Borczuk A, Phillips JA III, Palomero T, Sumazin P, Kim HR, Talati MH, West J, Loyd JE, Chung WK. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012;5:336–343. 83. Patel HH, Murray F, Insel PA. Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol. 2008;48:359–391. 84. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;8:185–194. 85. Frank PG, Cheung MW, Pavlides S, Llaverias G, Park DS, Lisanti MP. Caveolin-1 and regulation of cellular cholesterol homeostasis. Am J Physiol Heart Circ Physiol. 2006;291:H677–H686. 86. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev. 2004;84:1341–1379. 87. Mercier I, Jasmin JF, Pavlides S, Minetti C, Flomenberg N, Pestell RG, Frank PG, Sotgia F, Lisanti MP. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab Invest. 2009;89:614–623. 88. Chidlow JH Jr, Sessa WC. Caveolae, caveolins, and cavins: com plex control of cellular signalling and inflammation. Cardiovasc Res. 2010;86:219–225. 89. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68:673–682. 90. Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol. 2003;285:L1179–L1183. 91. Xu Y, Buikema H, van Gilst WH, Henning RH. Caveolae and endothelial dysfunction: filling the caves in cardiovascular disease. Eur J Pharmacol. 2008;585:256–260.


Austin and Loyd The Genetics of Pulmonary Arterial Hypertension 201 92. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;276:38121–38138. 93. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci U S A. 2002;99:11375–11380. 94. Maniatis NA, Shinin V, Schraufnagel DE, Okada S, Vogel SM, Malik AB, Minshall RD. Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice. Am J Physiol Lung Cell Mol Physiol. 2008;294:L865–L873. 95. Frank PG, Hassan GS, Rodriguez-Feo JA, Lisanti MP. Caveolae and caveolin-1: novel potential targets for the treatment of cardiovascular disease. Curr Pharm Design. 2007;13:1761–1769. 96. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449–2452. 97. Murata T, Lin MI, Huang Y, Yu J, Bauer PM, Giordano FJ, Sessa WC. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med. 2007;204:2373–2382. 98. Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U, Swaney JS, Niesman IR, Schermuly RT, Pullamsetti SS, Thistlethwaite PA, Miyanohara A, Farquhar MG, Yuan JX, Insel PA. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J. 2007;21:2970–2979. 99. Mathew R, Huang J, Gewitz MH. Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiol Rev. 2007;15:143–149. 100. Zhao YY, Malik AB. A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. Trends Cardiovasc Med. 2009;19:238–242. 101. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovych V, Yuan JX, Wharton J, Malik AB. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest. 2009;119:2009–2018. 102. Bauer PM, Yu J, Chen Y, Hickey R, Bernatchez PN, Looft-Wilson R, Huang Y, Giordano F, Stan RV, Sessa WC. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc Natl Acad Sci U S A. 2005;102:204–209. 103. Bauer PM, Bauer EM, Rogers NM, Yao M, Feijoo-Cuaresma M, Pilewski JM, Champion HC, Zuckerbraun BS, Calzada MJ, Isenberg JS. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res. 2012;93:682–693. 104. Eyries M, Montani D, Girerd B, et al. Eif2ak4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46:65-69. 105. Lantuejoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol. 2006;30:850–857. 106. Best DH, Sumner KL, Austin ED, Chung WK, Brown LM, Borczuk AC, Rosenzweig EB, Bayrak-Toydemir P, Mao R, Cahill BC, Tazelaar HD, Leslie KO, Hemnes AR, Robbins IM, Elliott CG. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest. 2014;145:231–236. 107. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, Bristow MR, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst. 2003;4:27–30. 108. Hoeper MM, Tacacs A, Stellmacher U, Lichtinghagen R. Lack of association between angiotensin converting enzyme (ACE) genotype, serum ACE activity, and haemodynamics in patients with primary pulmonary hypertension. Heart. 2003;89:445–446. 109. Koehler R, Olschewski H, Hoeper M, Janssen B, Grünig E. Serotonin transporter gene polymorphism in a cohort of German patients with idiopathic pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Chest. 2005;128:619S. 110. Machado RD, Koehler R, Glissmeyer E, et al.. Genetic association of the serotonin transporter in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;173:793–797.

111. Willers ED, Newman JH, Loyd JE, et al.. Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;173:798–802. 112. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, O’connor DT, Yuan JX. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2007;292:C1837–C1853. 113. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, HoustenHarris T, Cheadle C, Gao L, Hummers LK, Champion HC, Garcia JG, Wigley FM, Tuder RM, Barnes KC, Hassoun PM. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res. 2008;151:197–207. 114. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105:1672–1678. 115. Hamid R,Cogan JD, Hedges LK, Austin E, Phillips JA 3rd, Newman JH, Loyd JE. Penetrance of pulmonary arterial hypertension is modulated by the expression of normal bmpr2 allele. Hum Mutat. 2009;30:649–654. 116. Aldred MA, Comhair SA, Varella-Garcia M, Asosingh K, Xu W, Noon GP, Thistlethwaite PA, Tuder RM, Erzurum SC, Geraci MW, Coldren CD. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182:1153–1160. 117. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14:703–718. 118. Germain M, Eyries M, Montani D, et al.. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet. 2013;45:518–521. 119. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, Harmar A. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 2004;109:2150–2155. 120. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2011;90: 373–382. 121. White K, Loughlin L, Maqbool Z, Nilsen M, McClure J, Dempsie Y, Baker AH, MacLean MR. Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics. 2011;43:417–437. 122. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, Lane K, Meyrick B, Loyd J. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics. 2008;1:45. 123. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227:115–124. 124. Belous AR, Hachey DL, Dawling S, Roodi N, Parl FF. Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Res. 2007;67:812–817. 125. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96: 1856–1865. 126. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA III. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J. 2009;34:1093–1099. 127. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835–842. 128. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thébaud B, Husain AN, Cipriani N, Rehman J. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 2010;121: 2661–2671. 129. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014;129: 786–797.


202 Circulation Research June 20, 2014 130. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3microRNA cluster 17/92 pathway. Circ Res. 2009;104:1184–1191. 131. White K, Loscalzo J, Chan SY. Holding our breath: the emerging and anticipated roles of microRNA in pulmonary hypertension. Pulm Circ. 2012;2:278–290. 132. Pavelescu A, Vanderpool R, Vachiéry JL, Grunig E, Naeije R. Echocardiography of pulmonary vascular function in asymptomatic carriers of BMPR2 mutations. Eur Respir J. 2012;40:1287–1289.

133. Jones DL, Sandberg JC, Rosenthal MJ, Saunders RC, Hannig VL, Clayton EW. What patients and their relatives think about testing for bmpr2. J Genet Counsel. 2008;17:452–458. 134. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:14S–34S. 135. Chan SY, Loscalzo J. The emerging paradigm of network medicine in the study of human disease. Circ Res. 2012;111:359–374.


Genetics of pulmonary arterial hypertension.

Genetics and genomics of pulmonary arterial hypertension.

Future breakthroughs in the genetics of pulmonary arterial hypertension.

The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension.

Pediatric pulmonary arterial hypertension.

[Epigenetics and genetics of pulmonary arterial hypertension--new insights from the last years].

Gestational pulmonary arterial hypertension.

Management of pulmonary arterial hypertension.

[Treatment of pulmonary arterial hypertension].

Diagnosis of pulmonary arterial hypertension.

Epidemiology of pulmonary arterial hypertension.

The metabolic basis of pulmonary arterial hypertension.

Persistent pulmonary arterial hypertension of the newborn.

The metabolic theory of pulmonary arterial hypertension.

pulmonary arterial hypertension in congenital heart disease and therapy of pulmonary arterial hypertension in children].

Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

The Critical Role of Pulmonary Arterial Compliance in Pulmonary Hypertension.

Iranian Pulmonary Arterial Hypertension Registry.

Biomarkers in pulmonary arterial hypertension.

Macitentan and pulmonary arterial hypertension.

Macitentan and pulmonary arterial hypertension.

Macitentan and pulmonary arterial hypertension.

The challenges in paediatric pulmonary arterial hypertension.

The right ventricle in pulmonary arterial hypertension.